Top-News

Atossa Therapeutics Aktie News

Aktie
WKN:  A2JJ99 ISIN:  US04962H5063 US-Symbol:  ATOS Branche:  Biotechnologie Land:  USA
0,674 €
-0,008 €
-1,17%
09:19:35 Uhr
Depot/Watchlist
Marktkapitalisierung *
89,46 Mio. €
Streubesitz
78,84%
KGV
-4,72
Index-Zuordnung
-

Atossa Therapeutics News

04.12.25 - PR Newswire
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum PR Newswire
02.12.25 - PR Newswire
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma PR ...
17.11.25 - PR Newswire
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-​Reviewed Publication and ...
12.11.25 - PR Newswire
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
06.11.25 - PR Newswire
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium PR Newswire
21.10.25 - PR Newswire
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-​Surveillance ...
15.10.25 - PR Newswire
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
Atossa Therapeutics to Present at the Maxim Growth Summit 2025 PR Newswire
14.10.25 - PR Newswire
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness PR Newswire
13.10.25 - PR Newswire
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
Atossa Advances Global Patent Strategy for Z-​Endoxifen with New Protection in Israel and Ongoing Renewals PR Newswire
06.10.25 - PR Newswire
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-​Enabling Activities PR Newswire
01.10.25 - PR Newswire
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones PR Newswire
08.09.25 - PR Newswire
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction PR Newswire
28.08.25 - PR Newswire
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference PR Newswire
20.08.25 - PR Newswire
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-​Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer PR Newswire
12.08.25 - PR Newswire
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
29.07.25 - PR Newswire
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer PR Newswire
02.06.25 - PR Newswire
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen PR Newswire
13.05.25 - PR Newswire
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
10.04.25 - PR Newswire
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-​Generation Antibody Therapies for Breast Cancer PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,14%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »